Methods that inform on dynamic metabolism that can be applied to clinical populations to understand disease progression and responses to therapeutic interventions are of great importance. This review perspective will highlight recent advances, development, and applications of the multivalent stable isotope tracer deuterium oxide (D 2 O) to the study of substrate metabolism with particular reference to protein, lipids, and nucleic acids, and how these methods can be readily applied within clinical and pharmaceutical research.
INTRODUCTION
The ability to determine the metabolic regulation of diseases, ageing, and trauma at the whole body or organ level has been a significant driver in scientific research. One of the major challenges to achieving this is how to capture the dynamic nature of metabolic processes in vivo, in humans. Stable isotopes are the research tool making this possible as they permit quantification of protein, lipid, and nucleic acid metabolism, which has traditionally been performed through the use of substrate-specific tracers (e.g. 13 C/ 15 N amino acid tracers, 13 C palmitate, and 2 H glucose) [1] . Recently, experimental use of the deuterium oxide (D 2 O) tracer, which can be considered 'nonsubstrate specific' (i.e. incorporating into all major macromolecules), has undergone a resurgence ( Fig. 1) [2] . Here, we consider how D 2 O is revolutionizing the study of in-vivo dynamic metabolism; we describe the basis of D 2 O implementation, focusing on its use in humans and recent technical advances that extend the utility of this tracer to study human substrate metabolism in vivo, in particular its rapidly progressing translation to a clinical setting. D 2 O was one of the first isotope tracers to be used in metabolic research soon after its discovery by Harold Urey in 1932, the seminal works of Schoenheimer, Rittenberg, and Ussing demonstrated incorporation of deuterium from D 2 O into many metabolic pools [1] . Once introduced into cellular pools, D 2 O equilibrates throughout all body water and is incorporated into metabolites via condensation/hydrolysis reactions involving water; crucially, this occurs in a constant and predictable manner (Fig. 1 ). Using appropriate D 2 O dosages, permits the measurement of a huge range of metabolic processes, from the synthesis of deuterated precursors and their subsequent incorporation into polymers can be made, for example, deuterated alanine into protein, glucose into glycogen, fatty acids into triglycerides, and ribose moieties into nucleic acids (RNA/DNA; Table 1 ) [2] . D 2 O has a slow elimination rate from human body water (t 1 / 2 9-11 days) and so steady or pseudosteady state enrichments can be easily maintained by regular daily or weekly top-ups, providing the unique potential for measurements of metabolism to be performed over hours, days, weeks, or even months [3 & ,4-6] . Further, by collection of regular saliva (or urine) samples, body water enrichment can be easily monitored throughout, tracking with precursor labelling, enabling study participants to undertake their usual habitual activity and dietary regimes. These unique properties of D 2 O has made the popularity of its application, particularly to human research, increase exponentially over recent years. A major advantage of using D 2 O over substrate-specific tracers is the ease of administration, being orally consumed negating the need for sterile intravenous infusions, and a controlled laboratory environment, such that study participants can be studied 'free-living' over long periods [3 & ,6 ]. This provides a unique opportunity to metabolically phenotype a greater range of populations particularly in a clinical setting, where access has
KEY POINTS
Having methods that reveal the dynamic turnover of metabolic substrates are of great importance in unravelling diseases processes and in the future of personalized medicine. D 2 O has shown effectiveness at providing longer term, integrated, multisubstrate measures (proteins, lipids, nucleic acids) across a range of tissues and populations.
The ease of application and opportunities created to measure a range of substrates combined with the development of OMIC's methodologies, D 2 O has great potential to provide a more holistic picture of in-vivo metabolic in clinical populations. been restricted or contraindicated with intravenous tracers (i.e. in care homes, adolescents and so on).
RECENT PROGRESS IN USING DEUTERIUM OXIDE TO STUDY PROTEIN SYNTHESIS IN HUMANS
Although the application of D 2 O to the measurement of protein turnover dates back to the work of Hans Ussing in 1941, it is only in the past decade that its validity for measuring muscle protein turnover has been established and subsequently applied in humans [3 & ,4-6,7 & ]. Given the importance of skeletal muscle as a metabolic tissue in health and disease, it is unsurprising the application of these techniques has initially been focused on the measurement of muscle protein synthesis (MPS). Moreover, the accessibility of skeletal muscle for biopsy coupled to the slow turnover of the body water pool makes D 2 O ideally suited for application to the study of this slowly turning over metabolic pool. One of the first attempts to measure the rate of MPS in humans maintained body water around 2% over a 6-week period [by ingesting 150-ml D 2 O (70 atom percentage) per day during week 1 then 100-ml D 2 O daily thereafter]. In comparing a young sedentary and an older group undertaking an aerobic training program, the investigators showed greater MPS in the old group, demonstrating the utility of D 2 O for investigating the mechanisms of long-term 'anabolic interventions' [2] . By further refining, these principles with highly sensitive gas chromatography-pyrolysis-isotope ratio mass spectrometry (MS), substantial improvements in the analytical limit of detection and resolution were made, leading to the possibility of reduced D 2 O dosing, that is, a single bolus 150 ml 70 atom percentage, permitting MPS measurement over 8 days [6] . This is especially important when one considers the potential issue of nausea associated with consumption of increased volumes of D 2 O. Using these refined techniques we proved the concept that exercise-induced increases in myofibrillar, collagen, and sarcoplasmic fractional synthetic rates could be quantified over as little as 2 days, with measures of MPS over 3 h (in response to amino acid feeding) also possible, simply by increasing the D 2 O dose [7 & ]. Importantly, hourly MPS rates were identical to those we and others had shown in prior acute studies using stable-isotopically labelled amino acid and in direct comparison with substrate-specific amino acid tracers, D 2 O yielded quantitatively similar increases in MPS with feeding [7 & ]. Following these initial measures of MPS with D 2 O, a series of studies have demonstrated its wide applicability for the study of both short term (4-7 days) as well as longer term (4-8 weeks) interventions [3 & ,4-6] . Predominantly, these so far have been used to demonstrate what have been coined 'integrated' responses of MPS to a range of anabolic stimuli, including; resistance exercise, highintensity interval training [8] , aerobic exercise, and long-term (4 weeks) sprint interval training [9] . Further, we have demonstrated that there is Nucleic acid turnover DNA/RNA fast (>5% day) 150 ml þ 50 ml/week 150 ml þ 100-150 ml/day 1 day to 6 weeks 2 days to 6 weeks GC-pyr-IRMS GC-MS 0.0005% 0.5% DNA/RNA slow (<5% day) 150 ml þ 50 ml/week 150 ml þ 100-150 ml/day 1 day to 6 weeks 4-6 weeks
The dose of D 2 O and the analytical machinery required to ensure detection of desired substrates. The doses are taken from published examples or experimental calculations and can inform on the necessary D 2 O administration depending on the mass spectrometry instrumentation available. AP, atoms percent; D 2 O, deuterium oxide; GC-MS, gas chromatography-mass spectrometry; GC-pyr-IRMS, gas chromatography-pyrolysis-isotope ratio mass spectrometry; LC-HRMS, liquid chromatography-high resolution mass spectrometry; LOD, limit of detection. a Turnover rates of individual proteins and lipids vary and so earlier sampling is preferable to capture maximum number of analytes.
significant hypertrophy and structural remodelling in the early stages of resistance exercise (3 weeks) supported by integrated increases in MPS [10, 11] . Interestingly as training continued (up to 6 weeks), increased MPS was attenuated despite progressive intensity [10] , reflecting an adaptive waning to the anabolic stimulus. These studies have provided an integrated understanding of the role of protein turnover in regulating established physiological adaptation to exercise [2] . D 2 O has also been recently used in a more clinical context. Advanced ageing is associated with a continual and progressive decline in skeletal muscle mass, quality, and function [12] . Although the cause of this in humans remains poorly defined, it is clear that older individuals display blunted acute responses to anabolic stimuli such as feeding (particular amino acids and resistance exercise so-called anabolic resistance [12, 13] ). Using D 2 O to compare long-term MPS between young and older individuals, we were the first to demonstrate that blunted acute responses of MPS to exercise also manifest as long-term deficits in MPS [10] . This was not necessarily predictable given the lack of linkage between acute MPS responses to exercise and resulting muscle hypertrophy. Moreover, recently, it was shown that studying nutrition as well as exercise interventions was also feasible; in this study, the authors showed that adding supplemental leucine to meals could increase integrated MPS in older individuals [4] . These studies demonstrate that D 2 O applications have the potential to inform on integrated and temporal responses to nutrition and exercise interventions in a 'mechanistic fashion'. It is also of great interest that D 2 O has shown utility in a clinical setting in being applied to measure MPS in patients with upper gastrointestinal cancer. Using a single-bolus approach over 4 days immediately prior to surgery, patients losing weight had higher rates of MPS (0.073%/h) when compared to weight stable and controls (0.058%/h), possibly indicating greater protein turnover rates, although to lose muscle mass over time, protein breakdown would have to exceed MPS [14 & ]. Nonetheless, this study does show the feasibility of applying D 2 O in clinical populations; future work will expand the use of this tracer and seek both mechanistic insight of disease/ageing processes in addition to nutritional, exercise, or pharmacological interventions. Moreover, with the very recent introduction of dynamic proteomic techniques alongside the use of D 2 O, it is now possible to measure the turnover of a large number of individual proteins [9] rather than studying bulk myofibrillar or collagen protein fractions, as outlined by the recent 'virtual biopsy' technique [15] . These developments have opened up a whole new stream of measures to aid in the mechanistic understanding of human ageing and disease.
RECENT PROGRESS IN USING DEUTERIUM OXIDE TO STUDY FAT AND LIPID METABOLISM
Lipid metabolism has been the mainstay application of D 2 O for 80 years. Great technical and methodological refinement over the past 70 years punctuated by the seminal works of Jungas, Previs and Brunengraber and Hellerstein and Parks have engendered an array of D 2 O-based lipid assays. For example, by measuring the amount of deuterium incorporated from water into newly synthesized fatty acids, glycerol-3-phosphate, and/or cholesterol combined with mathematical modelling techniques, D 2 O has the unique potential for measuring rates of de novo lipogenesis, triglyceride synthesis (and turnover), and sterol biosynthesis simultaneously. The details, development and technical considerations for these techniques are beyond the scope of this review; the reader is directed to the following for more detail [1, 2, 16] .
Much of the progress over the past 5 years has been in how these novel D 2 O-based techniques can be applied (rather than further development of the isotopic theory of the models per se), particularly in terms of health, disease, and the rapidly evolving discipline of personalized medicine. For example, these techniques have helped to highlight the mechanisms underlying impaired adipose lipid metabolism in insulin-resistant humans (e.g. highlighting decreased adipose de novo lipogenesis and triglycerides synthesis: [17] ), the mechanisms driving the increase in adiposity associated with chronic insulin treatment (through an increase in triglyceride synthesis or inhibition of lipolysis and the alterations to cholesterol flux because of dyslipidaemia and coronary heart disease [18] . However, more recently, there has been marked progress in their implementation alongside high-throughput OMIC technologies, to gain a more holistic insight into the metabolic regulation of health and disease [16] . This has been in a large part driven by the rapid evolution of new MS technologies, in particular the introduction of high-resolution mass spectrometers such as Fourier Transform-MS and Orbitrap MS, which can provide isotopic resolution as high as 500 000 for some instrumentation. This increase in resolution when combined with liquid chromatography-high resolution mass spectrometers has provided capabilities for measuring low levels of 2H enrichment (comparable to that of traditional gold standard gas chromatography-isotope ratio MS techniques) of free fatty acids in a high throughput manner, alongside the measurement of associated whole lipid/lipoprotein species (in the form of lipidomics/proteomics). This has provided a unique analytical platform capable of determining how changes in lipid flux interact to influence the whole lipidome/lipoproteome, hence, providing exquisite insight the regulation and control of lipid metabolism and its interaction with other aspects of metabolism under health and disease in vivo using D 2 O. For example, incorporating traditional lipidomics with D 2 O permitted the measurement of dynamic changes in lipid profiles associated with dietary manipulation in animal models. Moreover, the simultaneous incorporation of D 2 O into highdensity lipoproteins (HDL), alongside cholesterol allows the measurement of the kinetics of HDL in vivo, an important technique which could greatly benefit the development of HDL-targeted therapies in conditions such as dyslipidaemia and atherosclerosis. Indeed, this has been the target in recent years with a number of recent studies utilizing these D 2 O techniques to provide a greater insight into the mechanisms and efficiency of a number of LDL cholesterol lowering therapies in particular. For example, D 2 O techniques have help to identify that the cholesterol ester transfer protein inhibitor anacetrapib was effective in promoting preb HDL formation potentially helping to lower LDL cholesterol levels, acting as a beneficial treatment for coronary heart disease. In addition, the administration of the cholesterol lowering drug ezetimibe was shown to increase the flux of plasma-derived cholesterol into faecal neutral sterols and hence increased excretion of cholesterol from the body, thereby helping to reduce LDL cholesterol formation and hence atherosclerosis. These studies highlight the added insight the inclusion of D 2 O to lipidomics can provide, and how these techniques will continue to benefit medical and pharmaceutical insight in future when combined alongside standard biochemical techniques and novel high-throughput OMICs platforms; this is clearly where the future lies for this niche technique.
RECENT PROGRESS IN THE USE OF DEUTERIUM OXIDE IN THE STUDY OF NUCLEOTIDE TURNOVER
There are many scenarios whereby the ability to quantify DNA and RNA turnover is desirable (e.g. tumourogenesis, skeletal muscle satellite cells, ribosomal biogenesis and so on). Yet to date, advances in the dynamic measurement of nucleotide metabolism have considerably lagged behind that of proteins and lipids because of the lack of suitable precursor compounds. Bromodeoxyuridine and tritiated (radioactive) thymidine have been utilized, although they are incorporated via salvage pathways that are variable and affected by extracellular nucleoside concentrations. Moreover, these analogues are toxic and cannot be used in humans. The potential use of D 2 O overcomes many of these restrictions by labelling nucleosides via de novo synthesis: a pathway (Fig. 1) that is upregulated during cellular division, is unaffected by extracellular nucleoside concentrations and rarely relies on reutilization. As such methods that are well tolerated for human use and measure cellular division are available [19] .
Initial measures of cellular proliferation using D 2 O in humans were that of fast turnover blood cells such as peripehral blood mononuclear cells. Outside of this, these techniques have been used over extended periods (4-6 weeks) to quantify DNA synthesis in skeletal muscle in response to nutritional and exercise interventions [2, 20] . This is an area of specific current interest as controversy still exists to the role of skeletal muscle stem cells (satellite cells), for example, in sarcopenia and exercise adaptation [21, 22] . With many disorders originating form altered cellular proliferation, these techniques have also been used to investigate; B and T-cell kinetics in patients with leukaemia or HIV, breast epithelial cells in both normal and tumour tissues, and in cellular areas defined as benign or cancerous from prostate tissue: all showing altered rates of proliferation. These methods have again, therefore, shown great potential for application in a clinical setting. Most recently, D 2 O was used to measure B-cell proliferation in patients with chronic lymphocytic leukaemia (CLL). Deuterium was first incorporated into CLL cells before treatment with the Bruton's tyrosine kinase inhibitor ibrutinib. By monitoring CLL DNA enrichment over the following weeks, it was demonstrated that ibrutinib dramatically decreases CLL cell birth via the lack of deuterium label dilution and hence proliferation of new cells [23 & ]. In addition to circulating cells, DNA synthesis rates have recently been made from tissue biopsies of fat, in attempts to link fat metabolism with obesity and insulin resistance. Storage of excess fat involves adipocyte hypertrophy along with preadiopacyte and adipocyte proliferation, with fat distribution and storage related to obesity-related diseases. To investigate this, pure adipocytes and preadipocytes were isolated after D 2 O labelling, identifying abdominal and femoral fat depots have different proliferation kinetics [24] . Furthermore, the rate of adipocyte replacement rates positively correlated with BMI and visceral adiposity but negatively correlated with insulin sensitivity: all signs of impaired metabolic health [25] .
Measures of RNA synthesis are also possible with D 2 O and have the potential to inform on dynamic ribosomal biogenesis: a primary determinant of protein synthesis rates during growth, cellular proliferation, and homeostasis. Deoxynucleotides are reduced from nucleotides and as such opportunities arise for the measurement of RNA synthesis using D 2 O; generally abiding by the same principles as above. Measurements of RNA synthesis in rodent liver have recently been made using D 2 O [26] ; however, currently, there is a lack of routine methods in the measurement of human RNA synthesis, particularly that in slow turnover tissues, that is, muscle. The development of such methods will have considerable impact in the clinical field, especially because of the loss of cell cycle control in many conditions such as cancer [27] . 
